NovoCure Ltd's U.S. subsidiary, Novocure Inc., had its billing privileges revoked retroactively to December 17, 2025, due to an administrative issue, affecting an estimated $13 million in monthly revenue until reinstatement. They have filed a Corrective Action Plan and continue serving patients but can't predict when privileges will be restored.